All In Biotech

Drug Trial Radar · NCT05800977

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

A Phase 1b/2 Study of a Anti-CD19/CD20 Bispecific CAR-T Therapy (C-CAR039/Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Feb 22, 2023

Primary completion

Mar 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Shanghai AbelZeta Ltd.Industry
Sponsor type
Industry
First posted
Apr 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).

Conditions

  • Relapsed/Refractory Large B-Cell Lymphoma

Interventions

  • Prizloncabtagene autoleucelBiological

    Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 90 days after C-CAR039 infusion
  2. Phase 1b: Recommended Phase 2 Dose (R2PD)Time frame: Up to 3 months after C-CAR039 infusion
  3. Phase 2: Overall Response Rate (ORR) at 3 monthsTime frame: Up to 3 months after C-CAR039 infusion

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Completed

  • Beijing GoBroad Hospital

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China · Recruiting

  • Chinese Academy of Medical Sciences Hematology Hospital

    Tianjin, China · Recruiting

  • Tianjin Medical University Cancer Institute& Hospital

    Tianjin, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.